Docetaxel vs non‐docetaxel‐containing regimens
Tumour response · people with advanced gastric cancer
Docetaxel probably leads to higher tumour response compared with non‐docetaxel‐containing regimens (moderate certainty).
4 findings from 1 review
- OR 1.37 [1.03, 1.83]9 studies · 1820 participantsModerate
- OR 1.03 [0.71, 1.5]4 studies · 525 participantsModerate
- OR 1.83 [1.45, 2.32]4 studies · 1235 participantsHigh
Show 1 more finding
- OR 0.33 [0.12, 0.96]1 study · 60 participantsVery low